🇺🇸 Pioglitazone and Glimepiride in United States

FDA authorised Pioglitazone and Glimepiride on 28 July 2006 · 15 US adverse-event reports

Marketing authorisation

FDA — authorised 28 July 2006

  • Application: NDA021925
  • Marketing authorisation holder: TAKEDA PHARMS USA
  • Indication: Labeling
  • Status: approved

Read official source →

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

Most-reported reactions

  1. Blood Glucose Increased — 3 reports (20%)
  2. Bronchitis — 2 reports (13.33%)
  3. Headache — 2 reports (13.33%)
  4. Product Dose Omission Issue — 2 reports (13.33%)
  5. Abnormal Dreams — 1 report (6.67%)
  6. Arthralgia — 1 report (6.67%)
  7. Completed Suicide — 1 report (6.67%)
  8. Condition Aggravated — 1 report (6.67%)
  9. Cough — 1 report (6.67%)
  10. Covid-19 Pneumonia — 1 report (6.67%)

Source database →

Pioglitazone and Glimepiride in other countries

Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.

Frequently asked questions

Is Pioglitazone and Glimepiride approved in United States?

Yes. FDA authorised it on 28 July 2006.

Who is the marketing authorisation holder for Pioglitazone and Glimepiride in United States?

TAKEDA PHARMS USA holds the US marketing authorisation.